Calcium-Phosphate Nanoparticles — a System for Drug Delivery to the Anterior Eye Chamber

Purpose: to prepare and characterize calcium-phosphate nanoparticles loaded with compounds of different nature: low-molecular inhibitor of angiotensin-converting enzyme lisinopril, and high-molecular enzyme superoxide dismutase 1. To estimate the possibility of enhancing the biological efficacy of t...

Full description

Saved in:
Bibliographic Details
Main Authors: O. V. Beznos, V. E. Tikhomirova, E. V. Popova, T. A. Pavlenko, O. A. Kost, N. B. Chesnokova
Format: Article
Language:Russian
Published: Ophthalmology Publishing Group 2021-07-01
Series:Oftalʹmologiâ
Subjects:
Online Access:https://www.ophthalmojournal.com/opht/article/view/1550
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849240955484372992
author O. V. Beznos
V. E. Tikhomirova
E. V. Popova
T. A. Pavlenko
O. A. Kost
N. B. Chesnokova
author_facet O. V. Beznos
V. E. Tikhomirova
E. V. Popova
T. A. Pavlenko
O. A. Kost
N. B. Chesnokova
author_sort O. V. Beznos
collection DOAJ
description Purpose: to prepare and characterize calcium-phosphate nanoparticles loaded with compounds of different nature: low-molecular inhibitor of angiotensin-converting enzyme lisinopril, and high-molecular enzyme superoxide dismutase 1. To estimate the possibility of enhancing the biological efficacy of these compounds via incorporation to the nanoparticles.Material and methods. To increase the stability of calcium-phosphate nanoparticles coating with β-D-cellobiose was used. The size, surface charge (ζ-potential) of the particles and efficacy of including of the selected compounds to the particles were measured. Comparative assessment of the efficacy of lisinopril solution and lisinopril in nanoparticles was made via the estimation of their ocular hypotensive effect in normotensive rabbits. To compare the efficacy of the superoxide dismutase 1 solution and superoxide dismutase 1 in nanoparticles the rabbit model of immunogenic uveitis was used. We estimated the clinical score for several signs of uveitis, protein level, and antioxidant activity in aqueous humor.Results. Calcium-phosphate nanoparticles containing lisinopril had average hydrodynamic radius of 170–300 nm and negative ζ-potential of –17 mV. Particles containing superoxide dismutase 1 had average hydrodynamic radius of 220–450 nm and negative ζ-potential of –4 mV. Lisinopril in nanoparticles caused a significantly greater decrease of intraocular pressure than lisinopril solution. Superoxide dismutase 1 in calcium-phosphate nanoparticles more efficiently decreased the clinical manifestations of uveitis and normalized the biochemical processes in aqueous humor than the enzyme in buffer solution.Conclusion. Incorporation of both low-molecular and high-molecular drugs to the calcium-phosphate nanoparticles enhance their bioavailability and therapeutic efficiency. The data obtained give evidence of the prospectively of the using of these nanoparticles as vehicles for the ophthalmic drugs used in eyedrops.
format Article
id doaj-art-6abc064e0ba74fc386612667a82d679f
institution Kabale University
issn 1816-5095
2500-0845
language Russian
publishDate 2021-07-01
publisher Ophthalmology Publishing Group
record_format Article
series Oftalʹmologiâ
spelling doaj-art-6abc064e0ba74fc386612667a82d679f2025-08-20T04:00:20ZrusOphthalmology Publishing GroupOftalʹmologiâ1816-50952500-08452021-07-0118233133710.18008/1816-5095-2021-2-331-337763Calcium-Phosphate Nanoparticles — a System for Drug Delivery to the Anterior Eye ChamberO. V. Beznos0V. E. Tikhomirova1E. V. Popova2T. A. Pavlenko3O. A. Kost4N. B. Chesnokova5Helmholtz National Medical Research Center of Eye DiseasesLomonosov Moscow State UniversityLomonosov Moscow State UniversityLomonosov Moscow State UniversityLomonosov Moscow State UniversityHelmholtz National Medical Research Center of Eye DiseasesPurpose: to prepare and characterize calcium-phosphate nanoparticles loaded with compounds of different nature: low-molecular inhibitor of angiotensin-converting enzyme lisinopril, and high-molecular enzyme superoxide dismutase 1. To estimate the possibility of enhancing the biological efficacy of these compounds via incorporation to the nanoparticles.Material and methods. To increase the stability of calcium-phosphate nanoparticles coating with β-D-cellobiose was used. The size, surface charge (ζ-potential) of the particles and efficacy of including of the selected compounds to the particles were measured. Comparative assessment of the efficacy of lisinopril solution and lisinopril in nanoparticles was made via the estimation of their ocular hypotensive effect in normotensive rabbits. To compare the efficacy of the superoxide dismutase 1 solution and superoxide dismutase 1 in nanoparticles the rabbit model of immunogenic uveitis was used. We estimated the clinical score for several signs of uveitis, protein level, and antioxidant activity in aqueous humor.Results. Calcium-phosphate nanoparticles containing lisinopril had average hydrodynamic radius of 170–300 nm and negative ζ-potential of –17 mV. Particles containing superoxide dismutase 1 had average hydrodynamic radius of 220–450 nm and negative ζ-potential of –4 mV. Lisinopril in nanoparticles caused a significantly greater decrease of intraocular pressure than lisinopril solution. Superoxide dismutase 1 in calcium-phosphate nanoparticles more efficiently decreased the clinical manifestations of uveitis and normalized the biochemical processes in aqueous humor than the enzyme in buffer solution.Conclusion. Incorporation of both low-molecular and high-molecular drugs to the calcium-phosphate nanoparticles enhance their bioavailability and therapeutic efficiency. The data obtained give evidence of the prospectively of the using of these nanoparticles as vehicles for the ophthalmic drugs used in eyedrops.https://www.ophthalmojournal.com/opht/article/view/1550calcium-phosphate nanoparticlesinhibitor of angiotensin-converting enzymesuperoxide dismutase 1intraocular pressureuveitis
spellingShingle O. V. Beznos
V. E. Tikhomirova
E. V. Popova
T. A. Pavlenko
O. A. Kost
N. B. Chesnokova
Calcium-Phosphate Nanoparticles — a System for Drug Delivery to the Anterior Eye Chamber
Oftalʹmologiâ
calcium-phosphate nanoparticles
inhibitor of angiotensin-converting enzyme
superoxide dismutase 1
intraocular pressure
uveitis
title Calcium-Phosphate Nanoparticles — a System for Drug Delivery to the Anterior Eye Chamber
title_full Calcium-Phosphate Nanoparticles — a System for Drug Delivery to the Anterior Eye Chamber
title_fullStr Calcium-Phosphate Nanoparticles — a System for Drug Delivery to the Anterior Eye Chamber
title_full_unstemmed Calcium-Phosphate Nanoparticles — a System for Drug Delivery to the Anterior Eye Chamber
title_short Calcium-Phosphate Nanoparticles — a System for Drug Delivery to the Anterior Eye Chamber
title_sort calcium phosphate nanoparticles a system for drug delivery to the anterior eye chamber
topic calcium-phosphate nanoparticles
inhibitor of angiotensin-converting enzyme
superoxide dismutase 1
intraocular pressure
uveitis
url https://www.ophthalmojournal.com/opht/article/view/1550
work_keys_str_mv AT ovbeznos calciumphosphatenanoparticlesasystemfordrugdeliverytotheanterioreyechamber
AT vetikhomirova calciumphosphatenanoparticlesasystemfordrugdeliverytotheanterioreyechamber
AT evpopova calciumphosphatenanoparticlesasystemfordrugdeliverytotheanterioreyechamber
AT tapavlenko calciumphosphatenanoparticlesasystemfordrugdeliverytotheanterioreyechamber
AT oakost calciumphosphatenanoparticlesasystemfordrugdeliverytotheanterioreyechamber
AT nbchesnokova calciumphosphatenanoparticlesasystemfordrugdeliverytotheanterioreyechamber